The ASCP Annual Meeting is the premier meeting each year in the field of psychopharmacology. Bringing together representatives from academia, the National Institutes of Health (NIH), Food and Drug Administration (FDA), European regulatory agencies, and industry to discuss key aspects of neuropsychiatric drug development, including the impact of diagnostic changes and personalized interventions based on biomarkers or genetic information. A Program Committee for the Annual Meeting chaired by Drs. Mark Rapaport and Tiffany Farchione including representatives from the ASCP Community, FDA, EMA, NIMH, NIDA, NIAAA, and the academia members, lead the direction of the meeting. The Review Subcommittee, under the leadership of Drs. Manish Jha and Carlos Blanco, are responsible for the review of all program submissions. To ensure the meeting includes the needs of our loyal pharmaceutical industry members, we are excited to announce the launch of the ASCP Industry Advisory Council led by Drs. Ross Baker and Julie Adams.

The ASCP Annual Meeting brings together over 900 academic and industry investigators, research pharmacists, and clinicians, including competitively selected New Investigator awardees.  ASCP is joined by federal partners, the National Institute of Mental Health (NIMH), National Institute on Drug Abuse (NIDA), National Institute on Alcohol Abuse and Alcoholism, (NIAAA) and the Food and Drug Administration (FDA) to organize a program that emphasizes the presentation of information that has not been previously published or presented. For more information about the history and purpose of the ASCP Annual Meeting please click here.

In recent years, the ASCP Annual Meeting focus has been expanded to address a number of timely issues relevant to clinical research in psychiatry, including the translation of research into practice, the importance of regulatory issues, and pharmacogenetics and other means to personalizing interventions.
For the 2024 Annual Meeting, ASCP is pleased to offer these plenary sessions and welcome these plenary speakers:

Clinical Updates in Neurotherapeutics | WEDNESDAY, MAY 29

- Jeffrey Newcorn M.D. | Icahn School of Medicine At Mount Sinai
- Mark Pollack M.D. | Biopharmaceutical Consulting
- Julia Riddle M.D. | University of North Carolina at Chapel Hill

 Update from Federal and Other Funding Agencies | THURSDAY, MAY 30

- Lori Davis M.D. | Veterans Affairs Medical Center
- Daniel Falk Ph.D. | NIAAA/NIH
- Fuad Issa M.D. | Defense Health Agency
- Ivan Montoya M.D.,M.P.H. | DHHS/National Institute on Drug Abuse
- Christopher Sarampote Ph.D. | National Institute of Mental Health
- Yu-Ping Wang M.D.,Other,M.Sc. Patient-Centered Outcomes Research Institute (PCORI)

Innovations in Clinical Research | THURSDAY, MAY 30

- Paul Kenny Ph.D. | Icahn School of Medicine at Mount Sinai
- Martina Pavlicova Ph.D. | Columbia University Medical Center
- Oleg Tcheremissine M.D. | Atrium Health

 Regulatory Plenary | WEDNESDAY, MAY 29 

- Teresa Buracchio M.D. | Center for Drug Evaluation and Research, Food and Drug Administration
- Michelle Campbell Ph.D. | Center for Drug Evaluation and Research, Food and Drug Administration
- Valentina Mantua M.D. | Center for Drug Evaluation and Research, Food and Drug Administration

Satellite Symposium Announced

Cultivating Inclusivity: Paving the Path to Improved Diversity in Clinical Trials | WEDNESDAY, MAY 29 | 7:30 – 8:30 PM

This session will explore the critical importance of improving diversity and inclusivity in clinical trials, so the results are generalizable and applicable to real-world patients encountered in clinical practice. Through insightful conversations and real-world examples, we aim to inspire a shift toward greater diversity, ensuring that clinical trials reflect the rich tapestry of the patient populations being treated. Provided by Clinical Care Options, LLC in partnership with American Society of Clinical Psychopharmacology. Supported by an educational grant from Otsuka America Pharmaceutical, Inc.

Regsitration is Required- Check back for Details

Embargo and Media Policy: Any press release issued by a presenter, the presenter's employer, or any other outside person or entity about a presentation scheduled for the ASCP Annual Meeting must be reviewed by the ASCP Officers and should be clear that it is not sanctioned by ASCP. Press releases do not need to be embargoed. All media personnel requesting waived access to ASCP meetings must provide a letter of request on company letterhead. Media requests will be reviewed and approved by the ASCP Officers.

Thank You to the 2024 Annual Meeting Sponsors

Gold Level Sponsor

Silver Level Sponsor

Submissions are closed for the 2024 ASCP Annual Meeting.

Listed below are the submissions accepted for the ASCP Annual Meetings.



  • Late-Breaking Posters– Late-breaking science included in the poster session.
    Deadline: March 18, 2024
  • Pharmaceutical Pipeline Presentations – A Pharmaceutical Pipeline report will be a 10 minute presentation and will also have the opportunity to present their research as a poster presentation. A Pharmaceutical Pipeline submission should include those with early clinical data (Phase 1 and 2) on any CNS compound for which Phase 3 data has not been presented. The goal is to generate enthusiasm for the many novel compounds under exploration, most of which have not reached Phase 3. This is not to exclude presentations of clinical data on compounds currently in Phase 3 targeted to truly untested mechanisms since such data would also be of great interest.
    Deadline: February 20, 2024
  • Poster Presentation – Poster board presentation in a general session.
    Deadline: February 14, 2024
  • Individual Research Report – Selected by the Program Committee, these are 10 minute oral presentation with 5 minutes Q&A from the audience.
    Deadline: February 14, 2024
  • Panel Sessions* – Have a Chair, a minimum of 3 Speakers but no more than 4 speakers, and a discussant. A co-chair is optional. Panel sessions are 1.5 hours in length.
    Deadline: November 13, 2023
  • Workshop Sessions* – Integrative session with a chair and no more than 8 participants. A discussant and co-chair is optional. Workshop sessions are 2 hours in length.
    Deadline: November 13, 2023


2023 ASCP Annual Meeting: May 30 - June 02, 2023

Please click on the links below to access virtual copies of pertinent meeting documents:

Presentation Slides are Available for the Below Sessions:

Regulatory Plenary: Pediatric Drug Development in Psychiatry

ASCP Lifetime Awardee Talk

Clinical Updates in Neurotherapeutics

Keynote Plenary: The Changing Landscape of Clinical Psychiatry: Novel Therapeutics, Methods and Assessments

Update From Federal and Other Funding Agencies Plenary

2022 ASCP Annual Meeting: May 31 - June 03, 2022

"Reassessing Research and Clinical Practice in the Peri-pandemic Era"
Fairmont Scottsdale Princess | Scottsdale, Arizona

Presentation Slides are Available for the Below Sessions:

Lifetime Awardee: Looking Back, Giving Thanks, and Moving Forward: Reflections on 50 Years as Physician/Scientist/Mentor in Geriatric Psychiatry

Clinical Updates in Psychopharmacology Session

    Update from Federal and Other Funding Agencies

    Regulatory Plenary

    2021 ASCP Annual Meeting: June 01 - 04, 2021

    Live Internet Course

    Lifetime Awardee: Adventures in Wonderland: The Circuitous Route from Stage and Screen through Decades in Academia to Digital Health Startup

    Clinical Updates in Psychopharmacology Session

    Keynote Plenary Session: Integrating New and Novel Treatments into Clinical Practice

    Federal Agency Updates Plenary

    Regulatory Plenary

    2020 ASCP Annual Meeting: May 29 - 30, 2020

    2019 ASCP Annual Meeting: May 28 - 31, 2019

    “Innovations in Personalized Medicine: From Biomarkers to Patient-Centered-Care”
    Fairmont Scottsdale Princess, Scottsdale, Arizona

    2018 ASCP Annual Meeting: May 29 - June 01, 2018

    “Treatment of Psychiatric Illness Across the Lifespan”
    Loews Miami Beach, Miami Beach, Florida

    2017 ASCP Annual Meeting: May 29 - June 02, 2017

    “Serving the Needs of the Diverse Population”
    Loews Miami Beach, Miami Beach, Florida

    2016 ASCP Annual Meeting: May 30 - June 03, 2016

    “Anticipating Future Interventions: Discovering New Targets, Integrative Biomarkers, and Beyond”
    Fairmont Scottsdale Princess, Scottsdale, Arizona

    2015 ASCP Annual Meeting: June 22 - 25, 2015

    “Staging Illness and Treatment:  From Prevention to Recovery”
    Loews Miami Beach Hotel, Miami, Florida

    2014 ASCP Annual Meeting (Formerly NCDEU): June 16 - 19, 2014

    “New Approaches to Mental Illness in the Era of the National Brain Initiative”
    Westin Diplomat, Hollywood, Florida

    2013 – 53rd NCDEU: An Annual Meeting Sponsored by ASCP: May 28 - 31, 2013

    “Recognizing Unmet Needs in Psychopharmacology: From Biomarkers to Breakthrough Therapies”
    Westin Diplomat, Hollywood Florida

    2012 – 52nd NCDEU Meeting: An Annual Meeting Sponsored by ASCP: May 29 - June 01, 2012

    “Identifying Common Targets across Brain Diseases – Implications for Treatment, Development and Delivery”
     Arizona Biltmore Resort & Spa, Scottsdale, Arizona

    2011 – 51st NCDEU Meeting: An Annual Meeting Sponsored by ASCP: June 13 - 16, 2011

    “Anticipating the Future of Drug Development:  New Targets, Integrative Biomarkers, and Beyond”
    Boca Raton Resort & Club, Boca Raton, Florida